Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography

NCT ID: NCT02113540

Last Updated: 2014-04-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

As the effect of statin use before the angiography to prevent contrast induced nephropathy (CIN) is not well-known, the aim of the current study is to assess the effect of atorvastatin on prevention of CIN in patients undergoing coronary angiography.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contrast Induced Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo group

taking atorvastatin like placebo 12 hours before the procedure

Group Type PLACEBO_COMPARATOR

No interventions assigned to this group

long term statin group

taking atorvastatin for a long time before entering the study (their routine treatment)

Group Type NO_INTERVENTION

No interventions assigned to this group

preoperation statin group

taking atorvastatin 12 hours before the procedure

Group Type EXPERIMENTAL

Atorvastatin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atorvastatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* having chronic stable angina who were referred for coronary angiography
* non-pregnant female subjects
* no history of diabetes mellitus
* no history of renal failure
* no history of single kidney
* no history of cardiogenic shock
* no history of unstable angina
* no history of myocardial infarction
* no history of hypersensitivity to statins
* no history of previous intravascular contrast injection during one month before admission

Exclusion Criteria

* glomerular filtration rate (GFR) \<60
* cardiogenic shock
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Isfahan University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

peyman bidram

Dr peyman bidram

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Isfahan, Isfahan, Iran

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Iran

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

payman bidram, resident, MD

Role: primary

0989131102802

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Grant number: 392172

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.